Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide
1990
How Pyrazinamide Affects Tumor Radiation Response
publication
Evidence: moderate
Author Information
Author(s): D.J. Chaplin, M.J. Trotter, K.A. Skov, M.R. Horsman
Primary Institution: B.C. Cancer Research Centre
Hypothesis
Does pyrazinamide enhance the radiation response of hypoxic tumor cells?
Conclusion
Pyrazinamide enhances the radiation response in certain murine tumors but not in hypoxic cells in vitro.
Supporting Evidence
- Pyrazinamide increased radiation response in EMT6, LLC, and SCCVII tumors.
- The dose modification factors ranged from 1.3 to 1.6 for the tumors.
- Pyrazinamide did not show radiosensitizing effects on hypoxic CHO cells in vitro.
- Blood flow studies indicated a 32% increase in tumor blood flow after pyrazinamide administration.
- Pyrazinamide reduced the number of vessels opening and closing in tumors.
Takeaway
Pyrazinamide helps tumors respond better to radiation, but it doesn't harm the cells in a lab dish.
Methodology
The study evaluated the effects of pyrazinamide on three murine tumor systems using in vivo and in vitro assays.
Limitations
The study primarily focused on murine models, which may not fully represent human responses.
Participant Demographics
The study used female Balb/C, C57B1/6, and C3H/He mice aged 2-3 months.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website